Previously posted:Your local compounding pharmacy making semaglutide in a back room is not the same as Novo Nordisk's billion-dollar manufacturing facility.
This is a straw man argument. Nobody is defending back-room operations. The well-run 503B outsourcing facilities have ISO-classified cleanrooms, validated HPLC testing, and FDA inspections. They're not mixing this stuff with a spoon in a closet.
And let's be real about the access issue — without compounding, millions of patients lose access to medications that are literally saving their lives. The brand manufacturers created a shortage they can't resolve. Compounding exists to fill that gap. That's the entire point of the 503 framework.